RxDoctor Payments Data

Elijah Stevens

Psychiatric/Mental Health · Binghamton, NYNPI 1326131954

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $102,450 of the $131,259 with a category attached, or 78.1%. 12 manufacturers reported payments, led by AbbVie at 46.3% of the total. Reporting peaked in 2021 at $42,862 and has fallen 76.1% since, to $10,254 in 2025. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$131,259in general payments, 2019–2025

Across 424 payments — averaging $309.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$61K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$51K
  • Alkermes, Inc.$17K
  • Teva Pharmaceuticals USA, Inc.$929
  • Otsuka America Pharmaceutical, Inc.$539
  • Johnson & Johnson$457
  • plus $502 from 6 others

What the payments were for

  • Consulting fees$7,7256%
  • Speaking & faculty fees$102,45078%
  • Travel & lodging$11,8609%
  • Food & beverage$9,1777%
  • Education$470%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$131,259 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate51$83,493
Abilify MaintenaAripiprazole14$39,983
VivitrolNaltrexone Microspheres13$22,077
Lamotrigine ErLamotrigine15$1,258
Aripiprazole13$547
Olanzapine19$370
Duloxetine Hcl24$216
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$197
Prazosin Hcl15$147
Hydroxyzine Hcl16$129
Quetiapine Fumarate26$108
Clonidine Hcl11$77
Trazodone Hcl24$50
Alprazolam20$30
Clonazepam13$15

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$51,191$83,49351 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$539$39,98314 claims
Alkermes, Inc.Vivitrol$16,878$22,07713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →